Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Review proposal consultation

Stakeholder matrix (PDF 219 KB)

Lung cancer (non-small-cell, first line) - gefitinib: review decision - December 2014 information

Lung cancer (non-small-cell, first line) - gefitinib: appendix A - GE decision paper - December 2014

Lung cancer (non-small-cell, first line) - gefitinib: appendix A - GE decision paper - December 2014 (PDF 496 KB)

Lung cancer (non-small-cell, first line) - gefitinib: review proposal october 2014 information

Lung cancer (non-small-cell, first line) - gefitinib: appendix b - proposal paper presented to the Institute's Guidance Executive

Lung cancer (non-small-cell, first line) - gefitinib: appendix b - proposal paper presented to the Institute's Guidance Executive (PDF 365 KB)

Lung cancer (non-small-cell, first line) - gefitinib: appendix a - provisional matrix of stakeholders

Lung cancer (non-small-cell, first line) - gefitinib: appendix a - provisional matrix of stakeholders (PDF 100 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination information

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination (PDF 199 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 93 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - clarification regarding potential issue with the economic model

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer-post 2nd AC meeting held on 4 March 2010

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer-post 2nd AC meeting held on 4 March 2010 (PDF 125 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer (addendum 9 March 2010)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer (addendum 9 March 2010) (PDF 108 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - letter sent by NICE to AstraZeneca 10 March 2010

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - letter sent by NICE to AstraZeneca 10 March 2010 (PDF 35 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - AstraZeneca letter of response 11 March 2010

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - AstraZeneca letter of response 11 March 2010 (PDF 26 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer 26 February 2010

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - Liverpool Reviews and Implementation Group (LRiG) comments on additional information provided by the manufacturer 26 February 2010 (PDF 100 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - AstraZeneca additional information sent in response to the Appraisal Consultation Document

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - AstraZeneca additional information sent in response to the Appraisal Consultation Document (PDF 1.06 MB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - AstraZeneca

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - AstraZeneca (PDF 15 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - British Thoracic Oncology Group

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - British Thoracic Oncology Group (PDF 91 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - British Thoracic Society

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - British Thoracic Society (PDF 29 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Department of Health

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Department of Health (PDF 28 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Eli Lilly

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Eli Lilly (PDF 30 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Cancer Research UK

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Cancer Research UK (PDF 341 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Roy Castle Lung Cancer Foundation

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Roy Castle Lung Cancer Foundation (PDF 41 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Nursing

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Nursing (PDF 22 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Pathologists

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Pathologists (PDF 15 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Physicians

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Royal College of Physicians (PDF 38 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Welsh Assembly Government

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - Welsh Assembly Government (PDF 36 KB)

Lung cancer (non-small-cell, first line) - gefitinib: final appraisal determination - consultee and commentator comments on the ACD - members of the public

Lung cancer (non-small-cell, first line) - gefitinib: update to consultees and commentators regarding 3rd appraisal Committee meeting

Lung cancer (non-small-cell, first line) - gefitinib: appraisal consultation document

Lung cancer (non-small-cell, first line) - gefitinib: appraisal consultation document information

Lung cancer (non-small-cell, first line) - gefitinib: evidence considered

Lung cancer (non-small-cell, first line) - gefitinib: ACD Pre-meeting briefing

Lung cancer (non-small-cell, first line) - gefitinib: ACD Pre-meeting briefing (PDF 163 KB)

Evidence Review Group report

Lung cancer (non-small-cell, first line) - gefitinib: ACD ERG Report

Lung cancer (non-small-cell, first line) - gefitinib: ACD ERG Report (PDF 566 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD Proforma for ERG report comments

Lung cancer (non-small-cell, first line) - gefitinib: ACD Proforma for ERG report comments (PDF 79 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD ERG report response to comments

Lung cancer (non-small-cell, first line) - gefitinib: ACD ERG report response to comments (PDF 65 KB)

Non-manufacturer submissions

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Royal College of Nursing

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Royal College of Nursing (PDF 39 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Royal College of Pathologists

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Royal College of Pathologists (PDF 21 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Royal College of Physicians

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Royal College of Physicians (PDF 56 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Roy Castle Lung Cancer Foundation

Lung cancer (non-small-cell, first line) - gefitinib: ACD non-manufacturers submissions - Roy Castle Lung Cancer Foundation (PDF 34 KB)

Manufacturer submissions

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca submission

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca submission (PDF 1.25 MB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca proposal for Patient Access Scheme

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca proposal for Patient Access Scheme (PDF 24 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca - NICE clarification letter

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca - NICE clarification letter (PDF 31 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca - response to NICE clarification letter

Lung cancer (non-small-cell, first line) - gefitinib: ACD manufacturers submissions - Astra Zeneca - response to NICE clarification letter (PDF 122 KB)

Expert statements

Lung cancer (non-small-cell, first line) - gefitinib: ACD expert written statements - Fox

Lung cancer (non-small-cell, first line) - gefitinib: ACD expert written statements - Fox (PDF 31 KB)

Lung cancer (non-small-cell, first line) - gefitinib: ACD expert written statements - Lind

Lung cancer (non-small-cell, first line) - gefitinib: final scope

Lung cancer (non-small-cell, first line) - gefitinib: Institute's response to consultee and commentator comments on the draft scope

Lung cancer (non-small-cell, first line) - gefitinib: final matrix

Lung cancer (non-small-cell, first line) - gefitinib: draft scope

Lung cancer (non-small-cell, first line) - gefitinib: provisional matrix